Autoimmune hepatitis (AIH) is characterized by an immune-mediated injury of the hepatic parenchyma of unknown pathogenesis. Type 2 AIH is identified by the presence of antiliver-kidney microsomes type 1 (anti-LKM1) and anti-liver cytosol type 1 (anti-LC1) autoantibodies. The current study shows that a murine model of AIH can be generated by DNA immunization against type 2 AIH self-antigens (P450 2D6 and formiminotransferase-cyclodeaminase). A pCMV plasmid containing the N-terminal region of mouse CTLA-4 and the antigenic region of human CYP2D6 (672-1,377 bp) and human formiminotransferase cyclodeaminase (FTCD; 1,232-1,668 bp) was used for DNA immunization of C57BL/6 female mice. Immunized mice showed elevated levels of alanine aminotransferase (ALT), with peaks at 4 and 7 months postinjection. Periportal, portal, and intralobular liver inflammatory infiltrates were observed at histology. Mainly CD4؉ lymphocytes, but also CD8؉ and B lymphocytes, were found in the liver. Cytotoxic-specific T cells were found in both the liver and spleen of these animals. Mice developed anti-LKM1 and anti-LC1 antibodies of immunoglobulin G2 (IgG2) subclass, against specific mouse autoantigens. The ALT levels correlated with both the presence of anti-LKM1/anti-LC1 antibodies and the presence of liver necroinflammation. In conclusion, in mice, DNA immunization against human autoantigens breaks tolerance and induces an autoimmune liver disease. Molecular mimicry between foreign and self-antigens explains the liver injury. This model of AIH resembles human type 2 AIH and will be helpful for the study of its pathogenesis. (HEPATOLOGY 2004;39:
-1074.)A utoimmune hepatitis (AIH) is a disorder of unknown etiology characterized by an immune-mediated injury that gradually destroys the hepatic parenchyma. Most patients have circulating autoantibodies, which are considered to be specific markers of the disease. 1 Two types of AIH are recognized, according to the autoantibodies found in sera samples. Type 1 AIH is characterized by the presence of anti-smooth muscle and/or anti-nuclear antibodies, whereas type 2 AIH shows anti-liver-kidney microsomal type 1 (anti-LKM1) and/or anti-liver cytosol type 1 (anti-LC1) antibodies. [2][3][4] Previous work has shown that the target of LC1 antibodies is formiminotransferase cyclodeaminase (FTCD) 5 and that anti-LKM1 antibodies are directed against P450 2D6 (CYP2D6). 6 These two enzymes are mainly expressed in hepatocytes. Titers of these autoantibodies show a good correlation with AIH activity and it has been speculated that they might play a role in the pathogenesis of this inflammatory disease. 7 Information obtained from clinical data can be applied to develop an animal model that will give new and broader insights into the relative importance of different factors involved in the pathogenesis of AIH.Several murine models of AIH have been described, but none of them are completely satisfactory. One of these models showed the development of a subacute hepatitis after immunization with a liver subcellular...